Were Richard Marshak’s TLSI share disposals discretionary open-market sales?

No, the filing states the shares were sold to satisfy tax withholding obligations. A footnote clarifies the transactions do not represent discretionary sales, but rather automatic disposals related to vesting of restricted stock units granted as compensation.

What is the purpose of the share sales disclosed in this TriSalus (TLSI) Form 4?

The purpose was to cover tax withholding obligations arising from vesting restricted stock units. The filing’s footnote emphasizes these sales were not discretionary investment decisions, but mechanical transactions tied to compensation-related equity vesting.

TriSalus (TLSI) CCO logs small tax-related share disposals, retains over 110K shares

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

TriSalus Life Sciences Chief Commercial Officer Richard Marshak reported routine share disposals tied to tax withholding, not discretionary selling. Over three days, he disposed of a total of 3,457 shares of common stock at prices between $4.09 and $4.13 per share. A footnote explains these shares were sold solely to satisfy tax obligations from vesting restricted stock units previously granted to him. After these transactions, Marshak continues to hold 110,397 shares of TriSalus common stock directly, indicating the disposals are small relative to his remaining stake.

Insider Trade Summary

Net Seller: 3,457 shares

Net Sell 3 txns

Insider Marshak Richard

Role Chief Commercial Officer

Sold 3,457 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Common Stock	419	$4.12	$2K
Sale	Common Stock	1,589	$4.09	$6K
Sale	Common Stock	1,449	$4.13	$6K

Holdings After Transaction: Common Stock — 110,397 shares (Direct)

Footnotes (1)

F1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/20/2026 - 04:25 PM

FAQ

What did TriSalus Life Sciences (TLSI) insider Richard Marshak report on this Form 4?

Richard Marshak reported disposing of 3,457 TriSalus common shares. The transactions occurred over three days in March at prices slightly above $4.00 per share and were linked to tax withholding on previously granted restricted stock units.

How many TriSalus (TLSI) shares did Richard Marshak dispose of and at what prices?

He disposed of 3,457 common shares in total. The reported per-share prices were $4.12, $4.09, and $4.13 on different days, reflecting small, tax-related transactions rather than large portfolio changes.

How many TriSalus (TLSI) shares does Richard Marshak hold after these transactions?

Following the reported tax-related disposals, Marshak directly holds 110,397 TriSalus common shares. This indicates the transactions affected only a small portion of his position, leaving his overall ownership in the company largely unchanged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marshak Richard

(Last)

(First)

(Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER

COLORADO

80031

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/11/2026		S		1,449⁽¹⁾	D	$4.13	112,405	D
Common Stock	03/12/2026		S		1,589⁽¹⁾	D	$4.09	110,816	D
Common Stock	03/16/2026		S		419⁽¹⁾	D	$4.12	110,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR